1. Home
  2. AIMD vs TCRX Comparison

AIMD vs TCRX Comparison

Compare AIMD & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ainos Inc.

AIMD

Ainos Inc.

SELL

Current Price

$1.24

Market Cap

10.6M

Sector

Health Care

ML Signal

SELL

Logo TScan Therapeutics Inc.

TCRX

TScan Therapeutics Inc.

SELL

Current Price

$0.14

Market Cap

11.8M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
AIMD
TCRX
Founded
1984
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.6M
11.8M
IPO Year
2008
2021

Fundamental Metrics

Financial Performance
Metric
AIMD
TCRX
Price
$1.24
$0.14
Analyst Decision
Hold
Analyst Count
0
5
Target Price
N/A
★ $1.00
AVG Volume (30 Days)
★ 4.0M
420.2K
Earning Date
11-16-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 12.28
EPS
N/A
★ N/A
Revenue
$124,157.00
★ $10,325,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 498.95
266.65
52 Week Low
$0.43
$0.14
52 Week High
$3.88
$1.47

Technical Indicators

Market Signals
Indicator
AIMD
TCRX
Relative Strength Index (RSI) 60.79 31.39
Support Level $0.50 N/A
Resistance Level $1.75 $0.21
Average True Range (ATR) 0.30 0.02
MACD 0.08 0.00
Stochastic Oscillator 51.47 8.07

Price Performance

Historical Comparison
AIMD
TCRX

About AIMD Ainos Inc.

Ainos Inc is a dual-platform company advancing artificial intelligence based smelltech technologies and immune therapeutics. Its primary strategic focus is the commercialization of its proprietary scent digitization platform, AI Nose, while the company also continue to develop therapeutic assets based on its low-dose oral interferon program, VELDONA. Its core technology platform, AI Nose, is an AI-based electronic olfaction system that integrates gas sensor arrays with proprietary artificial intelligence models, which it refers to as a smell language model (SLM), to digitize scent and volatile organic compound (VOC) signals into Smell ID, a machine-readable data format.

About TCRX TScan Therapeutics Inc.

TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Share on Social Networks: